Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting.
David Russell-JonesSimon R HellerSarah BuchsAnna SandbergWilliam J ValentineBarnaby HuntPublished in: Diabetes, obesity & metabolism (2017)
Faster aspart was associated with improved clinical outcomes and cost savings vs insulin aspart for patients with T1DM in the UK setting.